Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 15/20 | 0.81 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.74 |
| ▸ | RELA | Q04206 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7477872 | 0.93 | MRGPRX4 (0.74) | MRGPRX4NR4A2TP53PKMNFKB1 | |
| SCHEMBL4138759 | 0.91 | NR4A2 (0.81) | MRGPRX4NR4A2TP53PKMNFKB1 | |
| SCHEMBL4442371 | 0.90 | MRGPRX4 (0.71) | MRGPRX4NR4A2TP53PKMNFKB1 | |
| SCHEMBL3564078 | 0.90 | MRGPRX4 (0.72) | MRGPRX4NR4A2TP53PKMNFKB1 | |
| SCHEMBL3565096 | 0.90 | MRGPRX4 (0.92) | MRGPRX4NR4A2TP53PKMNFKB1 | |
| SCHEMBL3564888 | 0.90 | MRGPRX4 (0.92) | MRGPRX4NR4A2TP53PKMNFKB1 | |
| SCHEMBL3557661 | 0.90 | MRGPRX4 (0.92) | MRGPRX4NR4A2TP53PKMNFKB1 | |
| SCHEMBL3565625 | 0.90 | MRGPRX4 (1.00) | MRGPRX4NR4A2TP53PKMNFKB1 | |
| SCHEMBL4442592 | 0.89 | MRGPRX4 (0.70) | MRGPRX4NR4A2TP53PKMNFKB1 | |
| SCHEMBL4440879 | 0.89 | MRGPRX4 (0.71) | MRGPRX4NR4A2TP53PKMNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | claimed |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG AN | 2008-10-16 | — | — | US | claimed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1663936-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005000781-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE AG | 2004-12-30 | — | — | US | claimed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| WO-2020198537-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-8039495-B2 | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2005000781-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE AG | 2004-12-30 | — | — | US | disclosed |
| US-6080770-A | SUBSTITUTED 1,2,3-TRIAZOLE OR 1,2,4-TRIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 2000-06-27 | — | — | US | disclosed |
| US-6063800-A | Modulators of molecules with phosphotyrosine recognition units | NOVO NORDISK A/S (DK) | 2000-05-16 | — | — | US | disclosed |
| US-5972978-A | FOR USE IN TREATMENT OF HUMAN AND ANIMAL DISORDERS, USE FOR PURIFICATION OF PROTEINS OR GLYCOPROTEINS, USE IN DIAGNOSIS | NOVO NORDISK A/S (DK) | 1999-10-26 | — | — | US | disclosed |
| US-5958957-A | PROTEIN TYROSINE PHOSPHATASES, PROTEINS WITH SRC-MONOLOGY 2-DOMAINS; ANTICARCINOGENIC,-TUMOR AND DIABETIC AGENTS; PURIFICATION OF PROTEINS AND GLYCOPROTEINS; MEDICAL DIAGNOSIS | NOVO NORDISK A/S (DK) | 1999-09-28 | — | — | US | disclosed |
| WO-1997040017-A2 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | GYS2, GYS1, PYGL | MRGPRX4 2501/4885NR4A2 1083/4885TP53 4437/4885 |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885NR4A2 344/4885TP53 4046/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885NR4A2 344/4885TP53 4046/4885 |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885NR4A2 333/4885TP53 4026/4885 |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | MRGPRX4 1798/4885NR4A2 954/4885TP53 3978/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885NR4A2 344/4885TP53 4046/4885 |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885NR4A2 344/4885TP53 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.